Genetic Manipulation 7

Introduction to Induced Pluripotency

Induced pluripotency refers to the reprogramming of adult somatic cells to an embryonic stem cell-like state. The DNA in somatic adult cells is reprogrammable, which can be exploited for our benefit; however, this raises ethical concerns related to the disruption of blastocysts and the creation of human embryonic stem (ES) cells.

Cloning and Its Therapeutic Potential

Cloning via somatic cell nuclear transfer involves:

  • Taking a skin sample from a patient.

  • Isolating fibroblasts and removing the nuclei.

  • Inserting nuclei into unfertilized human oocytes to create blastocysts.

  • Extracting inner cell masses to develop embryonic stem cells for cell replacement.

Ethical consideration: The act of creating and destroying human blastocysts raises the question of when life begins.

Takahashi and Yamanaka's Breakthrough

2006: Takahashi and Yamanaka published "Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors" in Cell 126, 663-676. They proved that adult somatic cells can be induced to become pluripotent through the forced expression of a few key transcription factors: c-Myc, Oct4, Sox2, and Klf4, leading to the creation of induced pluripotent stem cells (iPS). This provided an alternative source of ES-like stem cells for regeneration.

Mechanism

  • Key genes required for maintaining pluripotency in ES cells and early embryos include Oct4, Nanog, and Sox2.

  • Several genes commonly expressed in tumors, such as Stat3, E-Ras, c-Myc, Klf4, and β-catenin, are essential for long-term maintenance of the ES cell phenotype and rapid proliferation in culture.

  • Takahashi and Yamanaka initially took 24 genes associated with pluripotency and cloned them into retroviruses to infect mouse cells in culture.

Method

  • They used mice whose Fbx15 gene had been replaced with a neomycin resistance marker.

  • Cultured somatic skin fibroblasts from these mice and infected them with retroviruses expressing the 24 genes.

  • Neomycin was added to the medium; only the survivors had induced pluripotency (iPS).

  • Their experiments indicated that forced expression of 10 genes was sufficient for pluripotency (iPS-MEF10 cells), and eventually, they found that the expression of the 4 genes (Oct4, Sox2, Klf4, and c-Myc) was enough to achieve induced pluripotency (iPS-MEF4 cells). Nanog was dispensable as it depended on the expression of Sox2.

Testing Pluripotency of iPSCs

To test whether the iPSCs had pluripotency like ES cells, they could be:

  • Implanted under the skin of an immunocompromised mouse.

  • Induced to form embryoid bodies by removing LIF.

The iPSCs with the 4 key genes generated teratomas, confirming their pluripotency, while iPSCs with only 3 genes produced tumors filled with undifferentiated cells, indicating a lack of pluripotency.

Mechanisms of Pluripotency Maintenance

Several genes are crucial for maintaining pluripotency in embryonic stem cells:

  • Nanog and Sox2: Key factors in maintaining the undifferentiated state.

  • c-MYC: An oncogene linked to cellular proliferation and transcription activation.

  • Beta-catenin: Functions within signaling pathways crucial for pluripotency.

Induced Pluripotent Stem Cells (iPSCs)

iPSCs were successfully generated from mouse somatic cells and later human cells, retaining the ability to:

  • Differentiate into various cell types (verification through teratoma formation in immunocompromised mice).

  • Contribute to all tissues in developing chimeric mice when injected into embryos.

  • Show clinical potential for regenerative medicine, especially for patient-specific therapies.

Safety and Ethical Considerations

The use of c-MYC poses a risk of tumorigenesis due to its role as an oncogene. Researchers continuously explore ways to ensure safety (e.g., removing oncogenes post-reprogramming). Ethical debates continue regarding the implications of iPSCs, especially concerning potential misuse of technology.

Applications in Disease Modeling and Therapy

Sickle cell anemia model:

  • Techniques to repair beta-globin gene mutations using patient-derived iPSCs demonstrate proof-of-principle for human application.

  • Skin fibroblasts of sickle cell mice were used to create iPSCs that were then corrected genetically and successfully reintroduced into the mice.

  • Potential applications in personalized medicine, drug testing, and effective therapies for genetic disorders.

Challenges and Future Directions

Epigenetic memory in iPSCs may hinder their efficiency and differentiation capabilities:

  • Some studies found iPSCs less effective in differentiating into cell types compared to embryonic stem cells.

  • The scientific community continues to work on refining methods to enhance the quality and efficiency of iPSCs.

  • Advances in culture conditions, gene editing capabilities, and understanding of cellular mechanisms enable broader applications of iPSCs in regenerative medicine.

Conclusion

Induced pluripotency has revolutionized stem cell research and holds significant promise for future therapies. The potential to create patient-specific cells offers tremendous advantages in treating a variety of conditions, but ongoing research is needed to address the technical and ethical challenges involved.